pharmaphorum Podcast

The importance of being disruption ready, with Brandon Pence

The cell culture media industry is currently experiencing significant growth, driven by the increasing demand for biopharmaceuticals, advancements in tissue engineering, and the rising number of research activities in cell biology.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Brandon Pence, who was recently appointed President and COO of Fujifilm Biosciences, a company previously known as Fujifilm Irvine Scientific, about the cell culture media field.
Pence also discusses end-to-end life sciences capabilities to create an accelerated path toward greater patient access for advanced care, as well as the shift of late to the US for many large pharma, during Trump’s second administration.
You can listen to episode 207a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

FH25: Commercialising Health Tech and Deeptech, with Pilar Fernández Hermida

This year marks the 10th anniversary of Frontiers Health.
In another episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with commercial strategy expert Pilar Fernández Hermida, founder of i-Expand, a commercial strategy firm focused on assisting Health Tech and Deeptech companies grow and monetise.
Fernández Hermida shares her favourite memory from the conference’s past decade, and discusses commercialisation of new technologies, such as advanced therapies and foundational tech like AI, and how CGTs can become more accessible, as well as much more.
Explore this Frontiers Health conversation and others - and find out how to attend the conference - here.

Agentic AI, culture shifts, and commercialisation today: Anthony Cilento post-Axtria Ignite 2025

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Anthony Cilento, vice president, data science & customer insights, at Bayer, in a post-Axtria Ignite 2025 discussion on the conference and agentic AI more generally.
Cilento speaks to the advancement from GenAI to agentic AI, what’s changed for his own team in this regard and what’s required by way of a culture shift more generally, as well as speaking to the changes necessary in the advanced therapies space when it comes to commercialisation.
You can listen to episode 206a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

FH25: On patient access and equity, with Roberta Sarno

This year marks the 10th anniversary of Frontiers Health.
In another episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with founder, director, and global health advisor at D-Health Consulting, Roberta Sarno. Sarno is also director of the APAC Liver Disease Alliance, and consultant on digital health APAC policy at the American Telemedicine Association, as well as advisor to the Asia Pacific Medical Technology Association.
Sarno discusses her favourite memory from Frontiers Health, as well as the importance of equity and accessibility for patients, and how that needs to be from day one. The conversation also touches upon the rural community experience, and explores global health innovation more widely, Sarno explaining why multistakeholder involvement is key.
Explore this Frontiers Health conversation and others - and find out how to attend the conference - here.

FH25: On healthcare innovation with Gary Monk

This year marks the 10th anniversary of Frontiers Health.
In another episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with healthcare innovation consultant Gary Monk.
Monk shares his favourite memory from the conference’s past decade, and discusses its ethos, as well as how his work at the moment aligns with that.
Explore this Frontiers Health conversation and others - and find out how to attend the conference - here.

FH25: The art of connection at Frontiers Health with Aline Noizet

Frontiers Health marks its 10th anniversary this year, celebrating a decade of innovation, collaboration, and the connections that drive progress.
 
In this episode of our Frontiers Health limited series of the pharmaphorum podcast, Deep Dive editor Eloise McLennan speaks with Aline Noizet, founder of Digital Health Connector  – a phrase that she says encapsulates both her personal mission and her 15 years of experience in the industry.
 
Noizet has built her career on connecting emerging start-ups with the partners who can help them grow, with the goal of ensuring that digital health solutions reach the patients who need them most. For her, Frontiers Health is about more than just ideas – it is about the relationships that make innovation possible.
 
Here, she reflects on the importance of creating these connections, the unique atmosphere of Frontiers Health, and some of her favourite moments from the past decade.

Policy in Focus: Trump’s Most Favoured Nations drug pricing scheme – with Alice Valder Curran

In Donald Trump's first presidential term, he spoke a lot about "Most Favoured Nations" pricing for pharmaceuticals - that is, bringing the prices that Americans pay for drugs in line with prices paid around the world. In his first term, all that talk didn't amount to much. But this time around the pharma industry is taking the President much more seriously.  
In today's pharmaphorum podcast, host Jonah Comstock speaks with Alice Valder Curran, a partner at Hogan Lovells and our go-to expert on US policy in pharma, for an update on what's happening right now with Most Favoured Nations drug pricing. 
Curran brings us up to speed on what's happened with the President's Executive Order and the industry response so far, then she and Comstock break down what was in the recent letters sent by the administration to major pharma companies and subsequently posted on Truth Social by the President. 
They talk about the short-term and long-term impacts of the policy, to what extent it's likely to come to fruition, and to what extent the industry has already begun to change its behaviour in response. Check out the full episode below to learn more about what could be the most impactful US policy change for pharma's bottom line in decades. 

FH25: Exploring the intersection of patients, HCPs, and technology with Denise Silber

Frontiers Health is back, and celebrating 10 years of innovation, conversation, and collaboration.
 
In this episode of our Frontiers Health limited series of the pharmaphorum podcast, Deep Dive editor Eloise McLennan speaks with Denise Silber, founder of Basil Strategies and Doctors 2.0.
 
Having spent more than two decades working at the intersection of healthcare professionals, patients, and technology, Silber has had a front row seat to the evolution of digital tools in the sector. From the early adoption of electronic health records to the integration of new artificial intelligence, she has witnessed dramatic shifts across life sciences, yet at the heart of her work remains the core focus of patient centricity.
 
In this interview, she discusses the importance of spotlighting patient centricity at Frontiers Health, what makes the event special, and her favourite moments from years gone by.  

Doing good in people’s lives: Amy Burroughs discusses CML

Chronic myeloid leukaemia (CML) is a unique disorder in the rare disease sector because there are multiple approved therapies for patients and, in the US alone, the prevalence of CML is expected to triple by 2040.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Amy Burroughs, CEO of Terns Pharmaceuticals, about available treatments for CML, the potential of allosteric TKIs, and the wider oncological landscape today.
You can also listen to episode 205a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

FH25: Individual centric investing with Steve Seuntjens

In this episode of our Frontiers Health limited series of the pharmaphorum podcast, Deep Dive editor Eloise McLennan speaks with Steve Seuntjens, Partner at PHS Capital.
 
Seuntjens has long been focused on investing in innovation that puts the individual at the centre of health. For him, building companies is never easy – but it becomes meaningful when the outcome is more engaged people, improved health results, and ultimately reduced costs. That, he believes, is where the true value of healthcare transformation lies.
 
He also shares some of his favourite moments from Frontiers Health, where ideas, energy, and people come together to push the boundaries of what’s possible in personal health innovation.